Olivier Bylicki

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Heather A. Wakelee, Moïshe Liberman, Terufumi Kato et al. · New England Journal of Medicine · 2023 · 903 citations · Full text

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 451 citations · Full text

Ifct-1501 Maps2, Immune Checkpoint Inhibitor, Pleural Disease +5

Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018

Florian Guisier, Catherine Dubos‐Arvis, F. Viñas et al. · Journal of Thoracic Oncology · 2020 · 287 citations · Full text

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee et al. · The Lancet · 2024 · 173 citations · Full text

Oncology, Adjuvant Pembrolizumab, Clinical Trials +8

Impact of Tobacco Smoking on the Risk of COVID-19: A Large Scale Retrospective Cohort Study

N. Paleiron, Aurélie Mayet, Vanessa Marbac et al. · Nicotine & Tobacco Research · 2021 · 145 citations · Full text